BIOR Short Interest Rises to More Than 243%
Biora Therapeutics (NASDAQ:BIOR) short interest has risen to more than 243%. More than double the company’s float is being shorted by big financial institutions. BIOR stock is up more than +71% this year-to-date but surged as much as +182% during…
Global Head of Operations at Citadel Has a Board Seat at DTCC
David Inggs is Global Head of Operations at Citadel and is responsible for all products across asset servicing, billing, cash management, clearing, and has a board seat at the DTCC. The conflict of interest has raised big concerns amongst the retail…
The Fed is Currently Investigating Goldman Sachs
The U.S. Federal Reserve is probing whether Goldman Sachs Group Inc’s consumer business had appropriate safeguards in place as the bank ramped up lending, the Wall Street Journal reported on Friday, citing people familiar with the…
Citadel’s Ken Griffin Sues IRS for Leaking Financial Data
[Bloomberg] Billionaire hedge fund manager Ken Griffin sued the US Internal Revenue Service, claiming it failed to protect his confidential financial information. The Citadel founder is seeking financial damages over a data breach that resulted in…
Is Biora Therapeutics (BIOR) Stock About to Go Big?
Biora Therapeutics (NASDAQ:BIOR), formerly known as PROG stock was up more than +182% in the first week of the new year. Today, BIOR stock is up more than +98% this year. The stock surged from $2 per share and peaked around $7.36 last Wednesday but…